NEW YORK, May 18, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ventrus Biosciences, Inc. ("Ventrus" or the "Company") (NASDAQ: VTUS).
The investigation focuses on whether the Company and its executives violated federal securities laws by issuing false and/or misleading statements and failing to disclose materially adverse facts concerning the Company's lead product iferanserin (VEN 309) ("VEN 309").
The Company described VEN 309 as a new chemical entity for the topical treatment of symptomatic internal hemorrhoids. According to Ventrus, VEN 309 demonstrated good tolerability and no severe adverse events while showing statistically significant improvements in bleeding, itchiness, and pain in seven clinical studies between 1993 and 2003. Moreover, the Company touted that the prior results from Phase II trials of VEN 309 demonstrated the product's clinical efficacy.However, Ventrus issued a press release on June 25, 2012 announcing that VEN 309 failed its Phase III trial, causing the Company to abandon further development of VEN 309, including any further attempt to obtain FDA approval. In response to this news, the price of Ventrus common stock plummeted over 50%, to $5.02 per share, on June 25, 2012. Request more information now by clicking here: www.faruqilaw.com/VTUS. There is no cost or obligation to you. Take Action
If you invested in Ventrus stock or options between December 17, 2010 and June 25, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/VTUS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Ventrus' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.FARUQI & FARUQI, LLP369 Lexington Avenue, 10th Floor New York, NY 10017Attn: Richard Gonnello, Esq. firstname.lastname@example.org Francis McConville, Esq. email@example.comTelephone: (877) 247-4292 or (212) 983-9330
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV